194 related articles for article (PubMed ID: 25488073)
1. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
Di Stefano AL; Labussiere M; Lombardi G; Eoli M; Bianchessi D; Pasqualetti F; Farina P; Cuzzubbo S; Gallego-Perez-Larraya J; Boisselier B; Ducray F; Cheneau C; Moglia A; Finocchiaro G; Marie Y; Rahimian A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M
J Neurooncol; 2015 Feb; 121(3):499-504. PubMed ID: 25488073
[TBL] [Abstract][Full Text] [Related]
2. Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
Rivoirard R; Chargari C; Guy JB; Nuti C; Peoc'h M; Forest F; Falk AT; Garin C; Adjabi A; Hoarau D; Fotso MJ; Langrand Escure J; Moriceau G; Fournel P; Boutet C; Magné N
Chemotherapy; 2016; 61(5):269-74. PubMed ID: 27057742
[TBL] [Abstract][Full Text] [Related]
3. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
6. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
7. Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.
Hattingen E; Bähr O; Rieger J; Blasel S; Steinbach J; Pilatus U
PLoS One; 2013; 8(3):e56439. PubMed ID: 23520454
[TBL] [Abstract][Full Text] [Related]
8. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
Martini M; de Pascalis I; D'Alessandris QG; Fiorentino V; Pierconti F; Marei HE; Ricci-Vitiani L; Pallini R; Larocca LM
BMC Cancer; 2018 May; 18(1):553. PubMed ID: 29747600
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Fangusaro J; Gururangan S; Poussaint TY; McLendon RE; Onar-Thomas A; Warren KE; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Kun LE; Fouladi M
Cancer; 2013 Dec; 119(23):4180-7. PubMed ID: 24104527
[TBL] [Abstract][Full Text] [Related]
10. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
Blumenthal DT; Mendel L; Bokstein F
J Neurooncol; 2016 May; 127(3):493-502. PubMed ID: 26721244
[TBL] [Abstract][Full Text] [Related]
11. Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.
Labussière M; Cheneau C; Prahst C; Gállego Pérez-Larraya J; Farina P; Lombardi G; Mokhtari K; Rahimian A; Delattre JY; Eichmann A; Sanson M
Cancer Invest; 2016; 34(1):39-44. PubMed ID: 26735326
[TBL] [Abstract][Full Text] [Related]
12. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.
Tabouret E; Boudouresque F; Barrie M; Matta M; Boucard C; Loundou A; Carpentier A; Sanson M; Metellus P; Figarella-Branger D; Ouafik L; Chinot O
Neuro Oncol; 2014 Mar; 16(3):392-9. PubMed ID: 24327581
[TBL] [Abstract][Full Text] [Related]
13. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Gajjar A; Goldman S; Friedman HS; Packer RJ; Boyett JM; Kun LE; McLendon R
Neuro Oncol; 2012 Nov; 14(11):1404-12. PubMed ID: 23019233
[TBL] [Abstract][Full Text] [Related]
14. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.
Auer TA; Renovanz M; Marini F; Brockmann MA; Tanyildizi Y
J Neurooncol; 2017 Jul; 133(3):571-579. PubMed ID: 28555422
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
[TBL] [Abstract][Full Text] [Related]
16. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
Jakobsen JN; Hasselbalch B; Stockhausen MT; Lassen U; Poulsen HS
Expert Opin Pharmacother; 2011 Apr; 12(5):825-33. PubMed ID: 21385110
[TBL] [Abstract][Full Text] [Related]
20. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
Cohen MH; Shen YL; Keegan P; Pazdur R
Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
